@article{TAU7245,
author = {Joseph J. Janicki and Michele A. Gruber and Michael B. Chancellor},
title = {Intravesical liposome drug delivery and IC/BPS},
journal = {Translational Andrology and Urology},
volume = {4},
number = {5},
year = {2015},
keywords = {},
abstract = {Intravesical therapy has previously shown to be effective in delaying or preventing recurrence of superficial bladder cancer. This local route of drug administration is now demonstrating promise in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) with the benefit of minimal systemic side effects. Liposomes (LPs) are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core. They can incorporate drug molecules, both hydrophobic and hydrophilic, and vastly improve cellular uptake of these drug molecules via endocytosis. Intravesical LPs have therapeutic effects on IC/BPS patients, mainly due to their ability to form a protective lipid film on the urothelial surface and repair the damaged urothelium. This review co},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/7245}
}